

[欧文論文]

1. Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naïve early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. *Ann Rheum Dis.* 75(1):75-83, 2016.
2. Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, van der Heijde D, Miyasaka N, Koike T. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. *Ann Rheum Dis.* in press
3. Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yasuoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yamanaka H, Yamamoto K, Takeuchi T. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). *Ann Rheum Dis.* 75(11):1917-23, 2016.
4. Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, Yamanaka H. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naïve patients with rheumatoid arthritis: The FIRST Bio study. *Mod Rheumatol.* in press.
5. Zhang P, Weaver JC, Chen G, Beretov J, Atsumi T, Qi M, Bhindi R, Qi JC, Madigan MC, Giannakopoulos B, Krilis SA. The Fifth Domain of Beta 2 Glycoprotein I Protects from Natural IgM Mediated Cardiac Ischaemia Reperfusion Injury. *PLoS One.* 11(3):e0152681, 2016.
6. Sada KE, Harigai M, Amano K, Atsumi T, Fujimoto S, Yuzawa Y, Takasaki Y, Banno S, Sugihara T, Kobayashi M, Kobayashi M, Usui J, Yamagata K, Homma S, Dobashi H, Tsuboi N, Ishizu A, Sugiyama H, Okada Y, Arimura Y, Matsuo S, Makino H; for Research Committee of Intractable Vasculitis Syndrome and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan. Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. *Mod Rheumatol.* 26(5):730-7, 2016.
7. Sakashita T, Kamishima T, Kobayashi Y, Sugimori H, Tang M, Sutherland K, Noguchi A, Kono M, and Atsumi T. Accurate quantitative assessment of synovitis in rheumatoid arthritis using pixel-by-pixel, time-intensity curve shape analysis. *Br J Radiol.* 89(1061):20151000, 2016.
8. Sugiyama N, Kawahito Y, Fujii T, Atsumi T, Murata T, Morishima Y, Fukuma Y. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. *Clin Ther.* 38(6):1359-75. e1, 2016.

9. Sakano R, Saito K, Kamishima T, Nishida M, Horie T, Noguchi A, Kono M, Sutherland K, Atsumi T. Power Doppler signal calibration in the finger joint between two models of ultrasound machine: a pilot study using a phantom and joints in patients with rheumatoid arthritis. *Acta Radiol.* in press
10. Fukae J, Tanimura K, Isobe M, Kitano A, Henmi M, Nakai M, Aoki Y, Sakamoto F, Narita A, Ito T, Mitsuzaki A, Matsuhashi M, Shimizu M, Kamishima T, Atsumi T, Koike T. Active synovitis in the presence of osteitis predicts residual synovitis in patients with rheumatoid arthritis with a clinical response to treatment. *Int J Rheum Dis.* in press
11. Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Ikeuchi S, Kushimoto S, Koike T. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. *Mod Rheumatol.* in press
12. Yasuda S, Shimizu Y, Atsumi T. Brain MRI abnormalities defined as risks for poor prognosis in lupus patients with acute confusional state: Are they antibody mediated? *Mod Rheumatol.* 30:1, 2016.
13. Yasuda S. Presence of Antiphospholipid Antibodies as a Thrombotic Risk Factor in Connective Tissue Diseases and Idiopathic/immune Thrombocytopenic Purpura--Proposal for Altered Cut-off values for Better Prediction. *Intern Med.* 55(6):557-8, 2016
14. Hirano F, Yokoyama W, Yamazaki H, Amano K, Kawakami A, Hayashi T, Tamura N, Yasuda S, Dobashi H, Fujii T, Ito S, Kaneko Y, Matsui T, Okuda Y, Saito K, Suzuki F, Yoshimi R, Sakai R, Koike R, Kohsaka H, Miyasaka N, Harigai M; T2T Epidemiological Study Group. Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy. *Mod Rheumatol.* in press.
15. Yasuda S, Ohmura K, Kanazawa H, Kurita T, Kon Y, Ishii T, Fujieda Y, Jodo S, Tanimura K, Minami M, Izumiyama T, Matsumoto T, Amasaki Y, Suzuki Y, Kasahara H, Yamauchi N, Kato M, Kamishima T, Tsutsumi A, Takemori H, Koike T, Atsumi T. Maintenance Treatment using Abatacept with Dose Reduction after Achievement of Low Disease Activity in Patients with Rheumatoid Arthritis (MATADOR) – A prospective, multicenter, single arm pilot clinical trial. *Mod Rheumatol.* in press
16. Amengual O, Forastiero R, Sugiura-Ogasawara M, Otomo K, Oku K, Favas C, Delgado Alves J, Zigon P, Ambrozic A, Tomsic M, Ruiz-Arruza I, Ruiz-Iratorza G, Bertolaccini ML, Norman GL, Shums Z, Arai J, Murashima A, Tebo AE, Gerosa M, Meroni PL, Rodriguez-Pintó I, Cervera R, Swadzba J, Musial J, Atsumi T. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. *Lupus.* in press.
17. Guturi KK, Bohgaki M, Bohgaki T, Srikumar T, Ng D, Kumareswaran R, El Ghamrasni S, Jeon J, Patel P, Eldin MS, Bristow R, Cheung P, Stewart GS, Raught B, Hakem A, Hakem R. RNF168 and USP10 regulate topoisomerase II $\alpha$  function via opposing effects on its ubiquitylation. *Nat Commun.* 7:12638, 2016.

18. Oku K, Amengual O, Hisada R, Ohmura K, Nakagawa I, Watanabe T, Bohgaki T, Horita T, Yasuda S, Atsumi T. Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome. *Rheumatology (Oxford)*. 55(8):1403-11, 2016.
19. Oku K, Amengual O, Kato M, Bohgaki T, Horita T, Yasuda S, Sakamoto N, Ieko M, Norman GL, Atsumi T. Significance of fully automated tests for the diagnosis of antiphospholipid syndrome. *Thromb Res*. 146:1-6, 2016.
20. Oku K, Nakamura H, Kono M, Ohmura K, Kato M, Bohgaki T, Horita T, Yasuda S, Amengual O, Atsumi T. Complement and thrombosis in the antiphospholipid syndrome. *Autoimmun Rev*. 15(10):1001-4, 2016.
21. Naoi T, Kameda T, Oku K, Ando A, Hayashi Y, Miyamoto M, Suzuki H, Kawakami T. Internal carotid artery occlusion and cerebral infarction in a case of juvenile systemic lupus erythematosus and positive for phosphatidylserine dependent antiprothrombin antibody (aPS/PT). *Neurology and Clinical Neuroscience*. in press.
22. Otomo K, Amengual O, Fujieda Y, Nakagawa H, Kato M, Oku K, Horita T, Yasuda S, Matsumoto M, Nakayama KI, Hatakeyama S, Koike T, Atsumi T. Role of apolipoprotein B100 and oxidized low-density lipoprotein in the monocyte tissue factor induction mediated by anti-beta2 glycoprotein I antibodies. *Lupus*. 25(12):1288-98, 2016.
23. Kato M, Atsumi T. Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention. *Rheumatol Int*. 36(5):635-41, 2016.
24. Kato M, Ospelt C, Kolling C, Shimizu T, Kono M, Yasuda S, Michel BA, Gay RE, Gay S, Klein K, Atsumi T. AAA-ATPase p97 suppress apoptotic and autophagy-associated cell death in rheumatoid arthritis synovial fibroblasts. *Oncotarget*. 7(39):64221-32, 2016
25. Hatano K, Kamishima T, Sutherland K, Kato M, Nakagawa I, Ichikawa S, Kawauchi K, Saitou S, Mukai M. A reliability study using computer-based analysis of finger joint space narrowing in rheumatoid arthritis patients. *Rheumatol Int*. in press.
26. Fujieda Y, Amengual O, Matsumoto M, Kuroki K, Takahashi H, Kono M, Kurita T, Otomo K, Kato M, Oku K, Bohgaki T, Horita T, Yasuda S, Maenaka K, Hatakeyama S, Nakayama KI, Atsumi T. Ribophorin II is involved in the tissue factor expression mediated by phosphatidylserine-dependent antiprothrombin antibody on monocytes. *Rheumatology (Oxford)*. 55(6):1117-26, 2016.
27. Nestor J, Gata-Garcia A, Arinuma Y, Fujieda Y, Kowal C, Diamond B. Immune-mediated brain pathology: from autoantibodies to microglia. *Discov Med*. 22(121):201-7, 2016.

28. Karino K, Kono Michihito. HLA-B52-positive Aortitis with Antineutrophil Cytoplasmic Antibody-associated Vasculitis. *Intern Med.* 55(23):3545, 2016.
29. Kono Michihito, Kamishima T, Yasuda S, Sakamoto K, Abe S, Noguchi A, Watanabe T, Shimizu Y, Oku K, Bohgaki T, Amengual O, Horita T, Atsumi T. Effectiveness of whole-body magnetic resonance imaging for the efficacy of biologic anti-rheumatic drugs in patients with rheumatoid arthritis: a retrospective pilot study. *Mod Rheumatol.* in press
30. Kanda M, Yamanaka H, Kojo S, Usui Y, Honda H, Sotomaru Y, Harada M, Taniguchi M, Suzuki N, Atsumi T, Wada H, Baghdadi M, Seino K. Transcriptional regulator Bhlhe40 works as a cofactor of T-bet in the regulation of IFN-gamma production in iNKT cells. *Proc Natl Acad Sci U S A.* 113(24): E3394-E3402, 2016.
31. Shimizu Y, Yasuda S, Kako Y, Nakagawa S, Kanda M, Hisada R, Ohmura K, Shimamura S, Shida H, Fujieda Y, Kato M, Oku K, Bohgaki T, Horita T, Kusumi I, Atsumi T. Post-steroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE. *Autoimmun Rev.* 15(8):786-94, 2016.
32. Noguchi A, Kato M, Kono M, Ohmura K, Ohira H, Tsujino I, Oyama-Manabe N, Oku K, Bohgaki T, Horita T, Yasuda S, Nishimura M, Atsumi T. Bi-ventricular interplay in patients with systemic sclerosis-associated pulmonary arterial hypertension: Detection by cardiac magnetic resonance. *Mod Rheumatol.* in press.
33. Nakamura H, Odani T, Shimizu Y, Takeda T, Kikuchi H. Usefulness of tacrolimus for refractory adult-onset still's disease: Report of six cases. *Mod Rheumatol.* in press.
34. Nakamura H, Shibata Y, Takeda T. Sternoclavicular Joint Swelling in a Patient with Rheumatoid Arthritis. *J Rheumatol.* 43(11):2074-2075, 2016.
35. Nakamura H, Amengual O, Horita T, Kato M, Oku K, Bohgaki T, Yasuda S, Atsumi T. Acute aortic thrombosis related to antiphospholipid antibodies. *Lupus.* in press
36. Nakamura H, Sugai T, Kato M, Hatanaka K, Atsumi T. Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome during tocilizumab therapy for juvenile idiopathic arthritis. *Clin Exp Rheumatol.* in press.
37. Sugawara E, Kato M, Sato T, Takahashi K, Kono M, Hisada R, Kono M, Oku K, Bohgaki T, Yasuda S, Tsujino I, Tanaka S, Atsumi T. Diversity of Borderline Pulmonary Arterial Pressure Associated with Systemic Sclerosis: 3 Case series. *Mod Rheumatol Case Rep.* in press.
38. Sugawara E, Kato M, Hisada R, Oku K, Bohgaki T, Horita T, Yasuda S, Atsumi T. Treatment of Vasodilator-Resistant Mixed Connective Tissue Disease-Associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide. *Intern Med.* in press.

40. Kono M, Yasuda S, Atsumi T. Takayasu arteritis with varied size vessel involvements. *J Rheumatol.* in press.
41. Makiyama J, Kono Michihiro, Shimizu S. Concerns about study on maternal H1N1 influenza vaccination and offspring mortality. *BMJ (Clinical researched).* 352, i775, 2016.
42. Kobayashi K, Kono Michihiro, Shiraishi M. Severe acquired acrodermatitis enteropathica caused by anorexia nervosa. *The Journal of dermatology.* 43, 456-7, 2016
43. Shida H, Nakazawa D, Tateyama Y, Miyoshi A, Kusunoki Y, Hattanda F, Masuda S, Tomaru U, Kawakami T, Atsumi T, Ishizu A. The Presence of Anti-Lactoferrin Antibodies in a Subgroup of Eosinophilic Granulomatosis with Polyangiitis Patients and Their Possible Contribution to Enhancement of Neutrophil Extracellular Trap Formation. *Front Immunol.* in press

[欧文著書]

1. Amengual O, Bertolaccini ML and Atsumi T. Laboratory Markers with clinical significance in the antiphospholipid Syndrome. In *Antiphospholipid Syndrome in Systemic Autoimmune Diseases.* Edited by Cervera R, Khamashta MA. 2016, Chapter 4, p47-70
2. Amengual O and Atsumi T. Pathogenesis of antiphospholipid syndrome. In *Systemic lupus erythematosus, basic, applied and clinical aspects.* Edited by George C Tsokos. Academic Press. 2016, Chapter 56, p487-92
3. Bertolaccini ML, Amengual O, Artim-Eser B, Atsumi T, de Groot PG, de Laat B, Devreese K, Giles I, Meroni PL, Borghi MO, Rahman A, Rand J, Regnault V, Kumar R, Tincani A, Wahl D, Willis R, Zuily S, Sanna G. Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. In *Antiphospholipid Syndrome: Current Research Highlights and Clinical Insights* Edited by Doruk Erkan and Dr. Michael Lockshin. Publishers Springer Science and Business Media. 2016 in press
4. Oku K, Amengual O, Otomo K and Atsumi T. Disease and Risk Measurement Criteria in APS, Antiphospholipid score. In *Antiphospholipid Syndrome - Current Research Highlights and Clinical Insights.* Edited by Doruk Erkan and Dr. Michael Lockshin. Publishers Springer Science and Business Media. 2016 in press

[邦文論文・原著]

1. 村島温子、渥美達也、井上永介、大田えりか、奥健志、小澤伸晃、金子 佳代、後藤美賀子、齋藤滋、杉浦真弓、関口将軌、高橋尚人、出口雅士、中山雅弘、野澤和久、平井千裕、藤田太輔、松岡健太郎、松木祐子、Amengual O、三木明德、光田信明、森臨太郎、山田秀人、山本 亮、横山健次、和田芳直：「抗リン脂質抗体症候群合併妊娠の診療ガイドライン」

2. 保田晋助、河野通仁、嶋村抄苗、栗田崇史、小谷俊雄、渥美 達也：「全身性自己免疫疾患の臓器合併症の予後と免疫治療の進歩」日本臨床免疫学会雑誌、39(1)、8-17、2016

[邦文著書]

1. 渥美達也：「全身性エリテマトーデス」。176-97(日本リウマチ財団教育研修委員会および日本リウマチ学会生涯教育委員会 編:リウマチ病学テキスト、診断と治療社日、東京)(2016)
2. 保田晋助：「関節痛 (arthralgia)」。 (矢崎義雄 編集、内科学、朝倉書店、東京) (印刷中)
3. 保田晋助：「反射性交感神経性ジストロフィー」。 (七尾清 編、今日の治療指針 2016年版-私はこう治療している、医学書院、東京) (2016)
4. 堀田哲也、渥美達也：「全身性自己免疫疾患」。142-52(山田俊幸、大戸斉、渥美達也、三宅幸子、山内一由 編:新版 臨床免疫学 第3版、講談社、東京)(2016)
5. 堀田哲也：リウマチ性疾患に使用される薬剤、治療法「6. シクロホスファミド」。511(日本リウマチ財団教育研修委員会、日本リウマチ学会生涯教育委員会 編集、リウマチ学病学テキスト 改訂第2版、診断と治療社、東京)(2016)
6. 堀田哲也：「血球貪食症候群の早期診断と治療」。347-359(山岡邦弘、五野貴久、三森経世、桑名正隆 編集、リウマチ・膠原病ハイグレード、リウマチ・膠原病の合併症や諸問題を解く、文光堂、東京)(2016)
7. 堀田哲也：「凝固・線溶系」。96-98(永井良三総監修、上阪等責任編集、膠原病・リウマチ・アレルギー研修ノート、診断と治療社、東京)(2016)
8. 堀田哲也：「血管炎症候群」。231-254(イヤートピックス 2016-2017、メディックメディア、東京)(2016)
9. 奥健志：「妊娠とリウマチ性疾患—抗リン脂質抗体症候群」。72-74(編者代表 山本一彦/田中栄：リウマチ学病学テキスト改訂第2版、診断と治療社、東京都)(2016)
10. 加藤将：「抗リン脂質抗体」。 (内科外来診断 Navi、中外医学社、東京) (印刷中)
11. 加藤将、渥美達也：「全身性エリテマトーデス」。315-8(上阪等 責任編集:膠原病・リウマチ・アレルギー、診断と治療社、東京)(2016)
12. 大村一将、奥健志：「抗リン脂質抗体症候群の難治性病態」。417-428(リウマチ・膠原病診療ハイグレード、文光堂、東京)(2016)

13. 中村浩之、奥健志、渥美達也：「抗リン脂質抗体症候群の定義と臨床」。108-17（湯村和子 編集：新膠原病・血管炎の腎障害、東京医学社、東京）(2016)
14. 柴田悠平、奥健志、渥美達也：「抗リン脂質抗体症候群（APS）」。350-353（上阪等 責任編集：膠原病・リウマチ・アレルギー、診断と治療社、東京）(2016)
15. 大西直樹、渥美達也：「抗リン脂質抗体症候群」。235-42（田中良哉 企画：全身性エリテマトーデス、最新医学社、東京）(2016)

[邦文論文・総説]

1. 渥美達也：「慢性炎症の病態：全身性エリテマトーデス」 BIO Clinica、5、41-6、2016
2. 保田晋助：「ミコフェノール酸モフェチル」リウマチ科、56(3)、249-254、2016
3. 保田晋助：「全身性エリテマトーデスの血栓症および血管障害～抗リン脂質抗体症候群を中心に～」膠原病、180、5-9、2016
4. 保田晋助、河野通仁、嶋村抄苗、栗田崇史、小谷俊雄、渥美達也：「全身性自己免疫疾患の臓器合併症の予後と免疫治療の進歩」日本臨床免疫学会雑誌、39、8-17、2016
5. 坊垣暁之、渥美達也：「膠原病治療に対する末梢血幹細胞移植は免疫抑制剤治療を越えるか？」分子リウマチ治療、9、111-5、2016
6. 奥健志、渥美達也：「全身性エリテマトーデス」炎症と免疫（印刷中）
7. 加藤将：「生物学的製剤投与時の感染症予防投薬の適応」Rheumatology Clinical Research、5、108-11、2016
8. 嶋村抄苗、保田晋助：「ループス腎炎に対するミコフェノール酸モフェチルの国内での使用実態」リウマチ科、55(3)、298-302、2016
9. 大村一将、渥美達也：「薬物治療の新しい話題 Fc 領域を持たない TNF 阻害剤セルトリズマブ」：Bone Joint Nerve、6(2)、371-77、2016
10. 中村浩之、渥美達也：「抗リン脂質抗体症候群」Thrombosis Medicine、6、137-42、2016
11. 久田諒、渥美達也：「血栓性微小血管症 膠原病」血栓と循環、24、48-52、2016
12. 河野通大、渥美達也：「Rheumatology Q&A 全身性エリテマトーデスに対する免疫抑制治療中に多発肺粒状影および下肢蜂窩織炎が出現した女性、原因は？」Rheumatology Clinical Research、5、140-3、2016

13. 河野通大、加藤将、渥美達也 : 「抗リン脂質抗体症候群の対応抗原の構造と機能」 炎症と免疫、24(2)、89-94、2016
14. 柴田悠平、渥美達也 : 「IL-17, IL-12/23 標的治療」 Rheumatology Clinical Research、5、14-8、2016
15. 谷村瞬、渥美達也 : 「SLE:新規治療薬 : belimumab、HCQ、MMF を含めて」 Mebio、33、11-17、2016